Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 8078

#Repost “Some doctors are experimenting with adding nitric oxide to the mix, to help improve blood flow and oxygen to the least damaged parts of the lungs.”

Ironically enough nitric oxide improves blood oxygen flow, and also clears blood clots. Some patients who survive COVID19 have clots in the blood vessels in their lungs. We just have to wait and see.

(NEW YORK) — As health officials around the world push to get more ventilators to treat coronavirus patients, some doctors are moving away from using the breathing machines when they can. The reason: Some hospitals have reported unusually high death rates for coronavirus patients on ventilators, and some doctors worry that the machines could be harming certain patients.

Read more: Front Line Workers Tell Their Own Stories in the New Issue of TIME

Continue reading “Why Some Doctors Are Now Moving Away From Ventilator Treatments for Coronavirus Patients” | >

A mutant bacterial enzyme that breaks down plastic bottles for recycling in hours has been created by scientists.

The enzyme, originally discovered in a compost heap of leaves, reduced the bottles to chemical building blocks that were then used to make high-quality new bottles. Existing recycling technologies usually produce plastic only good enough for clothing and carpets.

The company behind the breakthrough, Carbios, said it was aiming for industrial-scale recycling within five years. It has partnered with major companies including Pepsi and L’Oréal to accelerate development. Independent experts called the new enzyme a major advance.

Read more | >

An early analysis of remdesivir, a drug developed by pharmaceutical firm Gilead, has shown that it may have improved severe symptoms of COVID-19 in 68% of patients after 18 days.

For the Gilead-funded study, doctors recruited 61 patients hospitalized with COVID-19 with oxygen saturation of 94% or less while breathing ambient air or receiving oxygen support. To receve remdesivir on a compassionate use basis (a program allowing the use of unapproved medicines when no other treatment options are available), on the first day of treatment, patients were administered 200mg of remesdevir, and then 100 mg daily on the remaining 9 days of treatment.

After 18 days of receiving the treatment, the doctors found just 53 patients who met the criteria following treatment for analysis. Among them, 36 (68%) had notable improvements in oxygen support class, including 17 patients receiving mechanical ventilation who were extubated. 25 patients were consequently discharged, while 7 died.

Read more | >

Within a week, many world leaders went from downplaying the seriousness of coronavirus to declaring a state of emergency. Even the most efficacious of nations seem to be simultaneously confused and exasperated, with delayed responses revealing incompetence and inefficiency the world over.

So this begs the question: why is it so difficult for us to comprehend the scale of what an unmitigated global pandemic could do? The answer likely relates to how we process abstract concepts like exponential growth. Part of the reason we’ve struggled so much applying basic math to our practical environment is because humans think linearly. But like much of technology, biological systems such as viruses can grow exponentially.

As we scramble to contain and fight the pandemic, we’ve turned to technology as our saving grace. In doing so, we’ve effectively hit a “fast-forward” button on many tech trends that were already in place. From remote work and virtual events to virus-monitoring big data, technologies that were perhaps only familiar to a fringe tech community are now entering center stage—and as tends to be the case with wartime responses, these changes are likely here to stay.

Read more | >